You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR AVONEX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AVONEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001785 ↗ Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 1998-09-01 HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP). Currently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue. The purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks. Patients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials.
NCT00030966 ↗ Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis Completed Elan Pharmaceuticals Phase 3 2002-01-01 The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
NCT00030966 ↗ Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis Completed Biogen Phase 3 2002-01-01 The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
NCT00037102 ↗ Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis Completed Biogen Phase 4 2001-07-01 The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.
NCT00037102 ↗ Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis Completed Consultants in Neurology Phase 4 2001-07-01 The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.
NCT00037102 ↗ Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis Completed MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute Phase 4 2001-07-01 The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and bi-monthly high dose intravenous methotrexate with Leucovorin rescue.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AVONEX

Condition Name

Condition Name for AVONEX
Intervention Trials
Multiple Sclerosis 34
Relapsing-Remitting Multiple Sclerosis 14
Multiple Sclerosis, Relapsing-Remitting 8
Relapsing Remitting Multiple Sclerosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AVONEX
Intervention Trials
Multiple Sclerosis 65
Sclerosis 59
Multiple Sclerosis, Relapsing-Remitting 34
Multiple Sclerosis, Chronic Progressive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AVONEX

Trials by Country

Trials by Country for AVONEX
Location Trials
United States 316
Canada 38
France 38
Poland 35
Germany 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AVONEX
Location Trials
California 18
North Carolina 17
New York 17
Texas 14
Ohio 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AVONEX

Clinical Trial Phase

Clinical Trial Phase for AVONEX
Clinical Trial Phase Trials
Phase 4 18
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AVONEX
Clinical Trial Phase Trials
Completed 52
Terminated 7
Withdrawn 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AVONEX

Sponsor Name

Sponsor Name for AVONEX
Sponsor Trials
Biogen 40
EMD Serono 2
Merck KGaA, Darmstadt, Germany 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AVONEX
Sponsor Trials
Industry 71
Other 30
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.